The poster says nausea and vomiting rates in the UBT251 trial look identical and may make it seem easier to tolerate than rivals. It's one user's analysis.
Recap by typeshit. Post by @JCanNuSH on X.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
He says the peptide has almost no human data and is only sold online as a research chemical, so both the compound and its sourcing carry unknown risks.
Biomea Fusion was set to release early results for its investigational obesity candidate on October 13, with shares at $1.44 in premarket trading.
Loading…